A study of treatment of haert failure with conditioned medium

A study of treatment of heart failure with human-derived mesenchymal stem cell conditioned medium

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1051220088

Enrollment

Registered

2022-09-14

Start date

2022-08-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

haert failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who did not have a satisfactory therapeutic effect with standard treatment 2. Patients who do not wish to be treated with the drugs used in standard treatment due to concerns about side effects, etc., and those who have been judged by the doctor that chronic pain treatment with conditioned medium is optimal. Target patients who meet the following criteria. 1. 18 years old and over 2. Have normal consent ability 3. Patientse with a blood NT-proBNP level of 900 pg / mL or higher 4. Patients who can obtain their free will consent in writing 5. Patients whose doctor have recognized the need for treatment

Exclusion criteria

Exclusion criteria: Patient who meet any of the following conditions are excluded 1. Have a history of or suspected of dementia 2. Users of narcotics or stimulants 3. Pregnant, breastfeeding 4. Judged unsuitable by the doctor

Design outcomes

Primary

Measure	Time frame
Changes in NT-proBNP.Changes in High-sensitivity CRP, galectin-3, adiponectin, total antioxidant capacity, NYHA (Heart Function Classification), ACCF/AHA (Heart Failure Stage Classification) . Grip strength, body composition (weight, muscle mass).	—

Secondary

Measure	Time frame
subjective symptoms, etc.	—

Contacts

Public ContactYoshiki Murata

Seihoku Clinic

mochizuki@shhc.jp+81-789981101

Outcome results